Market Place
Sourcing Support
Merck KGaA suffers major blow as MS drug fails in late-stage trials
06 Dec 2023 //
REUTERS
Merck KGaA`s MS drug passes durability test ahead of ph. 3 data
12 Oct 2023 //
FIERCE BIOTECH
Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit
11 Oct 2023 //
BUSINESSWIRE
Merck KGaA`s BTK inhibitor hit by partial clinical hold over safety concern
13 Apr 2023 //
ENDPTS
Initiation of New Patients on Evobrutinib Paused in the U.S.
12 Apr 2023 //
BUSINESSWIRE
Merck Highlights New Four-Year Efficacy and Safety Data for Evobrutinib
23 Feb 2023 //
BUSINESSWIRE
Merck Highlights New Data for Evobrutinib
26 Oct 2022 //
BUSINESSWIRE
EMD Serono Highlights New Data for Evobrutinib
26 Oct 2022 //
BUSINESSWIRE
Merck KGaA showcases durability of evobrutinib in MS
26 Oct 2022 //
FIERCEBIOTECH
Data: Evobrutinib Demonstrates a Significant Reduction in SEL with RMS
14 Oct 2021 //
BUSINESSWIRE
EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials
04 Oct 2021 //
BUSINESSWIRE
EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials
04 Oct 2021 //
BUSINESSWIRE
India will have to play key role in mass production of coronavirus vaccine
24 May 2020 //
ECONOMIC TIMES
Merck KGaA touts FDA `breakthrough` status
12 Sep 2019 //
ENDPOINTS NEWS
New data backs Merck’s segue into MS with BTK inhibitor
13 May 2019 //
PR NEWSWIRE
Zydus receives US FDA marketing nod for blood pressure drug chlorthalidone tabs
13 May 2019 //
PHARMABIZ
Merck KGaA says might strike partnership deal this year
23 Oct 2018 //
REUTERS
Phase II Data For Merck`S BTK Inhibitor Highlighted at ECTRIMS
12 Oct 2018 //
BIOCENTURY
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.